Hepatoblastoma and microRNA-483 Two Forms and One OutcomeMarco Salvatore1†, Armando Magrelli1†*, Valentini Flamini2, Andrea Brunati3, Eleonora Basso3, Renato Romagnoli3, Ezio David3 and Domenica Taruscio1
- *Corresponding Author:
- Dr. Armando Magrelli
National Centre for Rare Diseases
Istituto Superiore di Sanità
Viale Regina Elena
299 – 00161 Rome, Italy
E-mail: [email protected]
Received date: November 30, 2015; Accepted date:December 07, 2015; Published date: December 14, 2015
Citation: Salvatore M, Magrelli A, Flamini V, Brunati A, Basso E, et al. (2015) Hepatoblastoma and microRNA-483 Two Forms and One Outcome. J Genet Syndr Gene Ther 6:278. doi:10.4172/2157-7412.1000278
Copyright: © 2015 Salvatore M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hepatoblastoma (HB) is the most common liver cancer in infants younger than 3 years. Its onset has been associated with other genetic syndromes and some genetic and biochemical markers has been identified recently in this neoplasia. Nevertheless the patients have a poor prognosis and the resection or transplantation remains the only effective therapeutic approach. The identification of non-invasive markers may represent an innovative approach and may contribute to a more accurate histological classification of this tumor. We previously demonstrated that some microRNAs are helpful in discriminating HB from hepatocellular carcinoma. In this study, we describe the involvement of the two forms of microRNA-483 (-3p and -5p) in a selected cohort of HB patients who underwent surgical resection or liver transplantation. Differently from other liver diseases we observed that the quantitative expression of the two forms did not significantly changed among patients. Furthermore, 3p/5p ratio was different between HB and non-HB samples, being positive in the latter and negative in HB samples. Influence of concomitant treatments in the expression of miR-483 (i.e. chemotherapy, and immunosuppressive drugs) was also evaluated and no changes were found in the follow-up. In conclusion the expression and function of miR-483-3p/5p in HB still remains unclear and further studies are needed to elucidate the possible mechanisms that regulate the different strand selection between the two forms of microRNA-483 in patients affected by HB. We deem that the analysis of microRNA-483 different forms could be useful for the molecular identification of HB patients and the discrimination with non-HB patient.